WallStSmart
CMMB

Chemomab Therapeutics Ltd DRC

NASDAQ: CMMB · HEALTHCARE · BIOTECHNOLOGY

$1.77
-1.67% today

Updated 2026-06-05

Market cap
$12.96M
P/E ratio
P/S ratio
EPS (TTM)
$-1.12
Dividend yield
52W range
$1 – $5
Volume
0.0M

Chemomab Therapeutics Ltd DRC (CMMB) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-69.68%
ROA
-40.30%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2008$-2.97M
2009$-6.82M
2010$-584000.00
2011$-5.99M
2012$24.18M
2013$-5.83M
2014$-6.00M
2015$-7.50M
2016$-4.73M
2017$0.00$-9.81M
2018$0.00$13.28M
2019$0.00$27.12M
2020$0.00$-5.95M
2021$0.00$-12.48M
2022$0.00$-27.65M
2023$0.00$-24.22M
2024$0.00$-13.95M
2025$0.00$-8.99M

Frequently asked questions

How much free cash flow does CMMB generate?

CMMB produced $-11.22M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CMMB's balance sheet healthy?

CMMB holds $7.56M in cash and equivalents against — in long-term debt, on $12.33M of shareholder equity. That debt is best read against the cash flow the business throws off each year.